These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191 [TBL] [Abstract][Full Text] [Related]
45. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004 [TBL] [Abstract][Full Text] [Related]
46. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition. Mattoo AR; Joun A; Jessup JM Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826 [TBL] [Abstract][Full Text] [Related]
47. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297 [TBL] [Abstract][Full Text] [Related]
48. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270 [TBL] [Abstract][Full Text] [Related]
49. Olaparib for the treatment of metastatic prostate cancer. Dror CM; Wyatt AW; Chi KN Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071 [TBL] [Abstract][Full Text] [Related]
50. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629 [TBL] [Abstract][Full Text] [Related]
51. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276 [TBL] [Abstract][Full Text] [Related]
52. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948 [TBL] [Abstract][Full Text] [Related]
56. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Sui H; Shi C; Yan Z; Li H Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641 [TBL] [Abstract][Full Text] [Related]
58. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285 [TBL] [Abstract][Full Text] [Related]
59. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283 [TBL] [Abstract][Full Text] [Related]
60. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT Cells; 2020 Apr; 9(4):. PubMed ID: 32276472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]